Details: pack, label wording, sources, registration
Hepatiale Forte, Tablet
tablet, VetExpert
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
Optional oral nutritional/hepatoprotective adjunct after veterinary diagnosis and disease-specific treatment; not diagnosis, toxin rescue or proven disease-modifying monotherapy
4.7/10
Weak evidence support
Details →
vetman assessment
Hepatiale Forte
×
tablet, VetExpert
Assessed clinical scope Dog · Optional oral nutritional/hepatoprotective adjunct after veterinary diagnosis and disease-specific treatment; not diagnosis, toxin rescue or proven disease-modifying monotherapy · By mouth
Care setting Veterinarian-directed outpatient adjunct with exact-form dose review, concurrent-product screening and objective reassessment.
vetman score
4.7/10
Weak evidence support
Evidence confidence: Low
Georgia: Not a medicine · Verified on 22 Oct 2026
A transparent complementary feed with plausible adjunctive rationale but insufficient independent exact-form evidence for reliable clinical benefit.
Regulatory and scientific credibility 4.0/10
Exact composition, category and manufacturer instructions are traceable, but evidence is mainly manufacturer material and indirect literature rather than independent exact-form outcome or safety studies.
Clinical efficacy 4.0/10
A 20-dog manufacturer-hosted uncontrolled observation reported biomarker changes, but pooled Forte with Large Breed and did not establish causality, clinical outcomes or durability.
Safety and tolerability 5.5/10
Short manufacturer-linked dog observations reported no clinical adverse effects, but the sample is small and uncontrolled and exact long-term, reproductive, interaction and severe-disease safety remains unestablished.
Clinical practicality 5.5/10
Once-daily oral use is workable, but one tablet/15 kg creates unvalidated fractions in smaller dogs; crushing/mixing is described without a calibrated subdivision method.
Full-course cost-effectiveness -
No verified current Georgian patient-adjusted course price or evidence-based treatment duration is available, so cost is excluded.
Important safety and use flags
Complementary feed, not a medicine. Medicine-authorisation status is not applicable; this category neither proves nor disproves clinical efficacy. Adjunct only after diagnosis and disease-specific care. Do not substitute this product for indicated diet, antidote, antimicrobial, immunosuppression, copper management, biliary intervention or other treatment. No independent controlled exact-form outcome study was located. Manufacturer observations and ingredient mechanisms do not prove regeneration, fibrosis reversal, survival benefit or durable disease control. Do not transfer efficacy, safety or dose from another Hepatiale presentation, another phospholipid/silymarin formulation, human studies or intravenous studies. The one-tablet/15 kg rule creates small fractions in cats and small dogs. Crushing was reported, but equal distribution, fraction measurement and partial-tablet stability are not validated. Biochemical improvement is not equivalent to a patient-centred outcome. Define the intended clinical objective and a reassessment/stop point before starting. No regulator-grade adverse-event frequency or contraindication section is available. Review soy sensitivity, GI tolerance, age, severe organ disease and every concurrent medicine or supplement; Advanced also contains milk thistle and zinc. Avoid duplicate hepatoprotective ingredients and review polypharmacy. Native extracts and multi-ingredient products are not automatically interchangeable, and interaction magnitude is not established for the exact product. Monitor the diagnosed disease objectively with clinical status, appetite, weight and condition-appropriate liver biochemistry, imaging or histology. Stop or revise the plan if no defined benefit appears or disease progresses. Exact safety in pregnancy, lactation, breeding animals, neonates and long-term severe hepatic, renal or multisystem disease is not established; use only after explicit individual benefit-risk review. Assessment sources +
Close
Cat
Optional oral nutritional/hepatoprotective adjunct after veterinary diagnosis and disease-specific treatment; not diagnosis, toxin rescue or proven disease-modifying monotherapy
3.6/10
Poor / unconvincing
Details →
vetman assessment
Hepatiale Forte
×
tablet, VetExpert
Assessed clinical scope Cat · Optional oral nutritional/hepatoprotective adjunct after veterinary diagnosis and disease-specific treatment; not diagnosis, toxin rescue or proven disease-modifying monotherapy · By mouth
Care setting Veterinarian-directed outpatient adjunct with exact-form dose review, concurrent-product screening and objective reassessment.
vetman score
3.6/10
Poor / unconvincing
Evidence confidence: Low
Georgia: Not a medicine · Verified on 22 Oct 2026
A transparent complementary feed with workable label administration but no exact feline outcome evidence; use only as a monitored adjunct, not a treatment substitute.
Regulatory and scientific credibility 4.0/10
Exact composition, category and manufacturer instructions are traceable, but evidence is mainly manufacturer material and indirect literature rather than independent exact-form outcome or safety studies.
Clinical efficacy 2.5/10
No exact feline outcome study was located; the dog observation and ingredient mechanisms do not establish benefit in naturally occurring feline hepatobiliary disease.
Safety and tolerability 4.5/10
No exact feline target-animal safety study or adverse-event frequency is available. Manufacturer silence cannot prove safety; soy, GI tolerance, concurrent supplements and product-specific ingredients require review.
Clinical practicality 3.0/10
The one-tablet/15 kg rule requires a small unvalidated tablet fraction for a typical cat, with no score line or calibrated measuring method.
Full-course cost-effectiveness -
No verified current Georgian patient-adjusted course price or evidence-based treatment duration is available, so cost is excluded.
Important safety and use flags
Complementary feed, not a medicine. Medicine-authorisation status is not applicable; this category neither proves nor disproves clinical efficacy. Adjunct only after diagnosis and disease-specific care. Do not substitute this product for indicated diet, antidote, antimicrobial, immunosuppression, copper management, biliary intervention or other treatment. No independent controlled exact-form outcome study was located. Manufacturer observations and ingredient mechanisms do not prove regeneration, fibrosis reversal, survival benefit or durable disease control. Do not transfer efficacy, safety or dose from another Hepatiale presentation, another phospholipid/silymarin formulation, human studies or intravenous studies. The one-tablet/15 kg rule creates small fractions in cats and small dogs. Crushing was reported, but equal distribution, fraction measurement and partial-tablet stability are not validated. No exact-product feline clinical outcome study was located. Canine biomarker results and ingredient mechanisms cannot establish feline benefit or target-animal safety. No regulator-grade adverse-event frequency or contraindication section is available. Review soy sensitivity, GI tolerance, age, severe organ disease and every concurrent medicine or supplement; Advanced also contains milk thistle and zinc. Avoid duplicate hepatoprotective ingredients and review polypharmacy. Native extracts and multi-ingredient products are not automatically interchangeable, and interaction magnitude is not established for the exact product. Monitor the diagnosed disease objectively with clinical status, appetite, weight and condition-appropriate liver biochemistry, imaging or histology. Stop or revise the plan if no defined benefit appears or disease progresses. Exact safety in pregnancy, lactation, breeding animals, neonates and long-term severe hepatic, renal or multisystem disease is not established; use only after explicit individual benefit-risk review. Assessment sources +
Close
Administration route
By mouth
Registration
Georgia
Not a medicine
Not applicable (not a medicine)
Verified on: 22 Oct 2026
EU
Not a medicine
Not applicable (not a medicine)
Verified on: 22 Oct 2026
UK
Not a medicine
Not applicable (not a medicine)
Verified on: 22 Oct 2026
US
Not a medicine
Not applicable (not a medicine)
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified
Manufacturer schedule: dogs and cats, one tablet per 15 kg once daily. Crushing/mixing was used in a manufacturer-hosted dog observation, but equal distribution in a tablet fraction and dose accuracy for small patients are not validated.
Dose Species Weight Route Frequency Source
0.067 tablet/kg
One tablet per 15 kg daily; typical cats require a fraction, and equal distribution/measurement is not validated.
Cat
Any weight
By mouth
once daily
VetExpert Hepatiale Forte
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
Hepatiale Forte - current exact product composition and use instructions
VetExpert product information, 2026
0.067 tablet/kg
One tablet per 15 kg daily. Crushing and mixing were reported, but accurate small fractions are not validated.
Dog
Any weight
By mouth
once daily
VetExpert Hepatiale Forte
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
Hepatiale Forte - current exact product composition and use instructions
VetExpert product information, 2026
